← Back to Search

MRI After Radiosurgery for Brain Cancer

N/A
Recruiting
Led By Scott Floyd, M.D. Ph.D.
Research Sponsored by Duke University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Radiographic progression on post-SRS imaging at previously treated SRS site(s)
Patients must have been diagnosed with a metastatic solid tumor of any histological type except small cell lung cancer (SCLC), or lymphoma
Must not have
Unable to undergo contrasted MRI (e.g. incompatible medical device, inadequate renal function per standard institutional clinical protocol, contrast allergy)
Small cell lung cancer (SCLC) or lymphoma histology
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether adding an MRI sequence can help doctors better distinguish between radiation damage and tumor recurrence in patients who have had brain radiation surgery.

Who is the study for?
This trial is for adults over 18 with brain metastasis from solid tumors, excluding small cell lung cancer and lymphoma, who've had stereotactic radiosurgery (SRS). They must be candidates for brain surgery, able to undergo MRI with contrast, and have signed an informed consent.
What is being tested?
The study is testing if adding another sequence to the MRI scan can better differentiate between tumor regrowth and radiation damage in patients who've undergone SRS for brain metastases.
What are the potential side effects?
Since this trial involves only additional MRI imaging sequences without new drugs or invasive procedures, side effects are minimal but may include discomfort during the scan or reactions to contrast agents used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer has grown at the site previously treated with radiation.
Select...
I have been diagnosed with a metastatic cancer that is not small cell lung cancer or lymphoma.
Select...
I am 18 years old or older.
Select...
I have cancer that has spread to my brain and was treated with radiation.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot have an MRI with contrast due to a medical condition or allergy.
Select...
My cancer is either small cell lung cancer or lymphoma.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
number of negative MRI sequences along with negative tumor biopsies
number of positive MRI sequences along with positive tumor biopsies

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: MRIExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Duke UniversityLead Sponsor
2,462 Previous Clinical Trials
2,968,883 Total Patients Enrolled
Scott Floyd, M.D. Ph.D.Principal InvestigatorDuke Health

Media Library

MRI Clinical Trial Eligibility Overview. Trial Name: NCT04246879 — N/A
Brain Tumor Research Study Groups: MRI
Brain Tumor Clinical Trial 2023: MRI Highlights & Side Effects. Trial Name: NCT04246879 — N/A
MRI 2023 Treatment Timeline for Medical Study. Trial Name: NCT04246879 — N/A
~5 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top